What is WVE-007 studying for overweight and obesity?

WVE-007 is being studied to understand its safety, how it moves and works in the body, and its effects in adults with overweight or obesity. This study is sponsored by Wave Life Sciences USA, Inc and aims to gather information on different doses of this investigational drug.

Who may be eligible for this overweight and obesity clinical trial?

Adults aged 18 to 60 years with a body mass index (BMI) in specific ranges depending on the study part, and those with or without pre-Type 2 or Type 2 diabetes are eligible. Both males and females can participate. Certain health conditions and recent use of similar treatments may exclude participants. Please review eligibility criteria for more details.

Is there any cost to participate in this overweight and obesity clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses and other related costs may vary and are not guaranteed to be covered. Participants should plan accordingly for these potential expenses.

Actively Recruiting

Phase 1

Phase 2

Age: 18Years - 60Years

All Genders

Healthy Volunteers

ID06842186

Study of WVE-007 Given by Injection to Adults With Overweight or Obesity to Test Safety and How the Body Handles the Drug

Led by Wave Life Sciences USA, Inc. · Updated on 2026-06-02

296

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of increasing doses of WVE-007, a stereopure siRNA oligonucleotide, in adults living with overweight or obesity. The study includes two parts Part A focuses on single ascending doses in adults with overweight or obesity, and Part B involves repeated doses in two groups of adults with obesity who have pre-Type 2 diabetes or Type 2 diabetes. This Phase 12a study is randomized, double-blind, and placebo-controlled to carefully assess the investigational treatment.

CONDITIONS

Brief Title

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

Who Can Participate

Age: 18Years - 60Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Male and female participants aged 18 to 60 years
For Part A: BMI 28 to 35 kg/m2 stable for 3 to 6 months; BMI 28 to 40 kg/m2 allowed for cohort expansion
For Part B: BMI 35 to 50 kg/m2 inclusive
Healthy as determined by medical history, physical exam, and lab tests
For Part B: Thyroid stimulating hormone within normal range; may be on stable supplemental thyroid hormone
For Part B: Diagnosed with pre-Type 2 diabetes or Type 2 diabetes

You will not qualify if you...

History or presence of cardiovascular disease including heart failure (NYHA Class III or IV), myocardial infarction, or angina
History or presence of thyroid disorders
Medical history or diagnosis of liver disease causes
Use of any siRNA agent within the prior 12 months
Receipt of investigational agents within 90 days or 5 half-lives before first dose or follow-up from another trial
For Part B: Use of prescription medications like anti-obesity or psychiatric drugs within 14 days before first dose, except allowed antihypertensives and statins
For Part B: Taking more than 2 antihypertensive medications or recent dose changes
For Part B: Taking more than 1 cholesterol-lowering medication or recent dose changes
For Part B pre-T2D cohorts: Use of GLP-1 receptor agonists or dual incretin agonists within 4 months before screening
For Part B T2D cohorts: Use of insulin or medications stimulating insulin within 60 days before screening including sulfonylureas, meglitinides, GLP-1 receptor agonists, dual incretin agonists, and DPP-4 inhibitors

Research Team

Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of WVE-007 Given by Injection to Adults With Overweight or Obesity to Test Safety and How the Body Handles the Drug

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria